A Novel Lipidomic Strategy Reveals Plasma Phospholipid Signatures Associated with Respiratory Disease Severity in Cystic Fibrosis Patients

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2009 Nov 7

PMID 19893743

Citations 25

Authors

Ida Chiara Guerrera

Giuseppe Astarita

Jean-Philippe Jais

Dorota Sands

Anna Nowakowska

Julien Colas

Isabelle Sermet-Gaudelus

Martin Schuerenberg

Daniele Piomelli

Aleksander Edelman

Mario Ollero

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to search for lipid signatures in blood plasma from cystic fibrosis (CF) patients using a novel MALDI-TOF-ClinProTools strategy, initially developed for protein analysis, and thin layer chromatography coupled to MALDI-TOF (TLC-MALDI). Samples from 33 CF patients and 18 healthy children were subjected to organic extraction and column chromatography separation of lipid classes. Extracts were analyzed by MALDI-TOF, ion signatures were compared by the ClinProTools software and by parallel statistical analyses. Relevant peaks were identified by LC-MSn. The ensemble of analyses provided 11 and 4 peaks differentially displayed in CF vs healthy and in mild vs severe patients respectively. Ten ions were significantly decreased in all patients, corresponding to 4 lysophosphatidylcholine (18:0, 18:2, 20:3, and 20:5) and 6 phosphatidylcholine (36:5, O-38:0, 38:4, 38:5, 38:6, and P-40:1) species. One sphingolipid, SM(d18:0), was significantly increased in all patients. Four PC forms (36:3, 36:5, 38:5, and 38:6) were consistently downregulated in severe vs mild patients. These observations were confirmed by TLC-MALDI. These results suggest that plasma phospholipid signatures may be able to discriminate mild and severe forms of CF, and show for the first time MALDI-TOF-ClinProTools as a suitable methodology for the search of lipid markers in CF.

Citing Articles

Fatty acid abnormalities in cystic fibrosis-the missing link for a cure?.

Drzymala-Czyz S, Walkowiak J, Colombo C, Alicandro G, Storrosten O, Kolsgaard M iScience. 2024; 27(11):111153.

PMID: 39620135 PMC: 11607544. DOI: 10.1016/j.isci.2024.111153.

Prophages divert Staphylococcus aureus defenses against host lipids.

Zhou B, Pathania A, Pant D, Halpern D, Gaudu P, Trieu-Cuot P J Lipid Res. 2024; 65(12):100693.

PMID: 39505263 PMC: 11721228. DOI: 10.1016/j.jlr.2024.100693.

Investigating the Potential of Lipids for Use as Biomarkers for Glioblastoma via an Untargeted Lipidomics Approach.

Soylemez B, Bulut Z, Sahin-Bolukbasi S J Korean Neurosurg Soc. 2022; 66(2):133-143.

PMID: 36530132 PMC: 10009237. DOI: 10.3340/jkns.2022.0091.

The fatty acid imbalance of cystic fibrosis exists at birth independent of feeding in pig and ferret models.

Uc A, Strandvik B, Yao J, Liu X, Yi Y, Sun X Clin Sci (Lond). 2022; 136(24):1773-1791.

PMID: 36416119 PMC: 9747517. DOI: 10.1042/CS20220450.

Plasma Lipid Profiling Identifies Phosphatidylcholine 34:3 and Triglyceride 52:3 as Potential Markers Associated with Disease Severity and Oxidative Status in Chronic Obstructive Pulmonary Disease.

Ben Anes A, Ben Nasr H, Tabka Z, Tabka O, Zaouali M, Chahed K Lung. 2022; 200(4):495-503.

PMID: 35816208 DOI: 10.1007/s00408-022-00552-z.

References

Sermet-Gaudelus I, Dechaux M, Vallee B, Fajac A, Girodon E, Nguyen-Khoa T . Chloride transport in nasal ciliated cells of cystic fibrosis heterozygotes. Am J Respir Crit Care Med. 2005; 171(9):1026-31. DOI: 10.1164/rccm.200406-740OC. View

Kaluzny M, Duncan L, Merritt M, Epps D . Rapid separation of lipid classes in high yield and purity using bonded phase columns. J Lipid Res. 1985; 26(1):135-40. View

Eidelman O, Barnoy S, Razin M, Zhang J, McPhie P, Lee G . Role for phospholipid interactions in the trafficking defect of Delta F508-CFTR. Biochemistry. 2002; 41(37):11161-70. DOI: 10.1021/bi020289s. View

Wu Y, Xu Z, Henderson F, Ryan A, Yahr T, Mallampalli R . Chronic Pseudomonas aeruginosa infection reduces surfactant levels by inhibiting its biosynthesis. Cell Microbiol. 2006; 9(4):1062-72. DOI: 10.1111/j.1462-5822.2006.00852.x. View

Vaughan W, LINDGREN F, Whalen J, Abraham S . Serum lipoprotein concentrations in cystic fibrosis. Science. 1978; 199(4330):783-6. DOI: 10.1126/science.203033. View

Trudel S, Kelly M, Fritsch J, Nguyen-Khoa T, Therond P, Couturier M . Peroxiredoxin 6 fails to limit phospholipid peroxidation in lung from Cftr-knockout mice subjected to oxidative challenge. PLoS One. 2009; 4(6):e6075. PMC: 2698990. DOI: 10.1371/journal.pone.0006075. View

Gaggar A, Jackson P, Noerager B, OReilly P, McQuaid D, Rowe S . A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol. 2008; 180(8):5662-9. PMC: 3998665. DOI: 10.4049/jimmunol.180.8.5662. View

Ollero M, Laposata M, Zaman M, Blanco P, Andersson C, Zeind J . Evidence of increased flux to n-6 docosapentaenoic acid in phospholipids of pancreas from cftr-/- knockout mice. Metabolism. 2006; 55(9):1192-200. DOI: 10.1016/j.metabol.2006.05.002. View

Innis S, Hasman D . Evidence of choline depletion and reduced betaine and dimethylglycine with increased homocysteine in plasma of children with cystic fibrosis. J Nutr. 2006; 136(8):2226-31. DOI: 10.1093/jn/136.8.2226. View

10.

Ulane M, Butler J, Peri A, Miele L, Ulane R, Hubbard V . Cystic fibrosis and phosphatidylcholine biosynthesis. Clin Chim Acta. 1994; 230(2):109-16. DOI: 10.1016/0009-8981(94)90263-1. View

11.

Astarita G, Piomelli D . Lipidomic analysis of endocannabinoid metabolism in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 877(26):2755-67. PMC: 2723187. DOI: 10.1016/j.jchromb.2009.01.008. View

12.

Innis S, Davidson A, Melynk S, James S . Choline-related supplements improve abnormal plasma methionine-homocysteine metabolites and glutathione status in children with cystic fibrosis. Am J Clin Nutr. 2007; 85(3):702-8. DOI: 10.1093/ajcn/85.3.702. View

13.

Cawood A, Carroll M, Wootton S, Calder P . Is there a case for n-3 fatty acid supplementation in cystic fibrosis?. Curr Opin Clin Nutr Metab Care. 2005; 8(2):153-9. DOI: 10.1097/00075197-200503000-00008. View

14.

Clandinin M, Zuberbuhler P, Brown N, Kielo E, Goh Y . Fatty acid pool size in plasma lipoprotein fractions of cystic fibrosis patients. Am J Clin Nutr. 1995; 62(6):1268-75. DOI: 10.1093/ajcn/62.6.1268. View

15.

Freedman S, Blanco P, Zaman M, Shea J, Ollero M, Hopper I . Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med. 2004; 350(6):560-9. DOI: 10.1056/NEJMoa021218. View

16.

Kowalski M, Pier G . Localization of cystic fibrosis transmembrane conductance regulator to lipid rafts of epithelial cells is required for Pseudomonas aeruginosa-induced cellular activation. J Immunol. 2003; 172(1):418-25. DOI: 10.4049/jimmunol.172.1.418. View

17.

Ollero M, Brouillard F, Edelman A . Cystic fibrosis enters the proteomics scene: new answers to old questions. Proteomics. 2006; 6(14):4084-99. DOI: 10.1002/pmic.200600028. View

18.

Schiller J, Suss R, Arnhold J, Fuchs B, Lessig J, Muller M . Matrix-assisted laser desorption and ionization time-of-flight (MALDI-TOF) mass spectrometry in lipid and phospholipid research. Prog Lipid Res. 2004; 43(5):449-88. DOI: 10.1016/j.plipres.2004.08.001. View

19.

Rosenstein B, Zeitlin P . Cystic fibrosis. Lancet. 1998; 351(9098):277-82. DOI: 10.1016/S0140-6736(97)09174-5. View

20.

Innis S, Davidson A . Cystic fibrosis and nutrition: linking phospholipids and essential fatty acids with thiol metabolism. Annu Rev Nutr. 2008; 28:55-72. DOI: 10.1146/annurev.nutr.27.061406.093625. View